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Abstract
DNA vaccines might offer an alternative to the live smallpox vaccine in providing protective efficacy in an orthopoxvirus (OPV) lethal
respiratory challenge model. BALB/c mice were immunised with DNA vaccines coding for 10 different single vaccinia virus (VACV)
membrane proteins. After an intranasal challenge with the VACV IHD strain, three gene candidates B5R, A33R and A27L produced≥66%
survival. The B5R DNA vaccine consistently produced 100% protection and exhibited greatest efficacy after three 50g intramuscular
doses in this model. Sero-conversion to these vaccines was often inconsistent, implying that antibody itself was not a correlate of protection.
The B5R DNA vaccine induced a strong and consistent gamma interferon (IFN) response in BALB/c mice given a single DNA vaccine
dose. Strong IFN responses were also measured in pTB5R immunised C57BL6 mice deficient for MHC class I molecules, suggesting
that the memory response was mediated by a CD4+ T cell population.
Crown Copyright © 2004 Published by Elsevier Ltd. All rights reserved.
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1. Introduction
The World Health Organisation (WHO) announced the
eradication of smallpox in 1980 and subsequently recom-
mended that global vaccination should cease [1]. Routine
vaccination against smallpox has not been practised for over
20 years, leaving the population of the world increasingly
vulnerable. Today the majority of children and adults are
not vaccinated against smallpox, and the consequences of
a re-emergence of the disease, by whatever means, would
be far reaching without effective public health interventions
[2,3].
Infection with variola virus (VARV, the causative agent
of smallpox) can be initiated by just a few virions [4] and
patients remain asymptomatic for between 7 and 17 days.
The virus is transmitted principally by the aerosol route and
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can produce 100% morbidity and up to 40% mortality [1].
Clinical signs appear at the onset of a secondary viremia with
fever, followed by headache, backache and the development
of a distinctive rash [5,6]. Laboratory diagnosis can take
several days and may require biosafety level IV facilities.
The live smallpox vaccine (vaccinia virus) is admin-
istered by scarification, and results in swelling, irritation
and discomfort at the site of inoculation. The resulting le-
sion sheds live virus until scabbing occurs at 7–10 days
post-inoculation. Vaccination with the Lister (Elstree) or
Wyeth (New York City Board of Health) strains of VACV
was the method promoted by the WHO during the smallpox
eradication campaign in the 1960s and 1970s [1].
VACV and VARV both belong to the genus Orthpoxvirus,
that also includes monkeypox virus (MPXV). Monkeypox
is a very similar disease to smallpox and has a 1–14%
case-fatality rate and routinely causes severe infections in
young children. MPXV is an endemic/zoonotic OPV of
sub-Saharan Africa [7]. Infections are frequently transmit-
ted to man via infected bushmeat, but person-to-person
contact infection can occur, usually between close family
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Table 1
Information relating function and known antigenic properties of the VACV proteins selected for study
VACV gene Particle type Protein Requirement for
plaque formation
Neutralising
antibody
Protection (%) Description of
gene product
A13L IMV p8 Essential No [22]
A27L IMV p14 Essential Yes 10 [18] [23]
D8L IMV p32 Essential Yes [24]
H3L IMV p35 Essential No [25]
L1R IMV p25 Essential Yes 80 [17] [26]
A33R EEV gp23–28 (type II glycoprotein Essential No 100 [16], 70 [17] [27]
A34R EEV gp22–24 (type II glycoprotein Essential No 18 [16] [28]
A56R EEV gp86 (type I glycoprotein) Non-essential No [29]
B5R EEV gp42 (type I glycoprotein) Essential Yes 82 [16], 40 [18] [30]
A36R IEV gp43–50 (type Ib glycoprotein) Essential No 50 [16] [31]
members [8]. MPXV can be controlled with the smallpox
vaccine. A recent outbreak of MPXV in the USA highlights
the vulnerability of an unvaccinated population against this
poxvirus [9].
Primary vaccination with the current smallpox vaccine is
also associated with rare but life-threatening complications
[1]. Generalised vaccinia rash occurs as a result of a sys-
temic infection with transient viremia. Prognosis for this
condition is usually good. Eczema vaccinatum and progres-
sive vaccinia are life-threatening complications that result
from the pre-existing conditions of eczema or immunodefi-
ciency, respectively. Eczema and immunodeficicency in the
world population today are more common than 30 years ago
and so the risks associated with the current live smallpox
vaccine are significantly increased. Live vaccine also poses
the threat of accidential infection of the eye, perineum and
vulva [1] and the potential for infecting close-contacts such
as partners, friends and family.
Subunit vaccines can stimulate strong protective immune
responses with reduced side effects relative to complex live
or inactivated vaccines. Subunit vaccines have been previ-
ously adopted as safe and effective countermeasures for the
control of significant viral infections of man such as hepati-
tis B and influenza [10,11].
The mechanism of protection from VARV infection is
poorly understood. Studies with other viruses have iden-
tified virion surface antigens as key vaccine components
[12,11] perhaps because they have important functions for
the virus in cell adsorption, cell entry or virion egress.
The identification and characterisation of analogous com-
ponents of VACV (Table 1) provides the opportunity to
elucidate their importance in immunity by targeting in-
dividual proteins. All OPVs produce two types of virus
particle with distinct surfaces. The intracellular mature
virus (IMV) is retained within the infected cell whilst
the extracellular (EEV) form of virus is actively secreted
from cells and contributes to the efficient dissemination of
virus in vitro [13] and in vivo [14]. The EEV membrane
contains at least four viral proteins (Table 1). In addition,
cellular membrane proteins CD46, CD55, CD59, CD71,
CD81 and major histocompatibility complex (MHC) class
I antigens have been detected in purified EEV membranes
[15]. The surface of the IMV membrane contains a dif-
ferent set of proteins (Table 1). Recent published studies
have indicated that subunit protein and DNA vaccines de-
rived from two EEV proteins B5R and A33R are protective
[16].
Our studies compared DNA vaccines for 10 different EEV,
IMV and one intracellular enveloped virus (IEV) protein to
elucidate the efficacy of individual VACV membrane pro-
teins. We show that the EEV proteins B5R and A33R, as well
as one IMV protein, A27L, were the most effective in pro-
tecting BALB/c mice from a VACV challenge in this model.
The B5R DNA vaccine produced 100% protection and an
immediate and strong IFN response but did not produce re-
liable antibody responses, suggesting that the main element
of protection offered by this vaccine is by cell-mediated im-
munity.
2. Materials and methods
2.1. Production of DNA vaccines
The VACV genes used in this study included envelope
proteins from IMV, EEV and IEV (Table 1). These genes
were PCR amplified from VACV IHD-J DNA using Taq
DNA polymerase with the primer pairs listed in Table 2,
which contained initiation codons and stop codons in the
forward and reverse primers, respectively. Amplicons were
cloned directly into the mammalian expression vector pTar-
get (Promega). The gene inserts of individual clones were
orientated by restriction digestion and their DNA sequenced
(Oswel) to establish an intact and representative open read-
ing frame. Plasmid DNA was prepared in bulk from suitable
clones using the Qiagen endotoxin-free mega prep kit and
DNA was resuspended in sterile PBS. DNA concentrations
were determined by UV spectroscopy.
2.2. Administration of vaccine
Six-week-old female BALB/c or C57BL6 mice were
each immunised with 50g of endotoxin-free plasmid
DNA mixture containing 25% bupivicaine hydrochloride
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Table 2
Primers used to amplify VACV IHD-J genes by PCR
VACV gene Forward primer (reverse primer) Amplicon size (bp) Plasmid DNA vaccine
A13L 5′-GGAATTCGGATCCTAAAATGATTGGTATTCTTTTGTT-3′ 242 pTA13L
5′-CCCGGGCTCGAGTTATACAGAAGATTTAACTAGA-3′
A27L 5′-GATCGAATTCTAAAATGGACGGAACTCTTTTC-3′ 359 pTA27L
5′-AAGCTTCTCGAGTTACTCATATGGACGCCGT-3′
D8L 5′-GATCGAATTCAAAATGCCGCAACAACTATCTC-3′ 940 pTD8L
5′-CCCGGGCTCGAGCTAGTTTTGTTTTTCTCGCG-3′
H3L 5′-CCGATTTTAGTAATATGGAATAGTGTTAGA-3′ 1004 pTH3L
5′-ACTAAATGGCGGCGGTGAA-3′
L1R 5′-TATTTAAATGGGTGCCGCAGC-3′ 779 pTL1R
5′-TTTCTAGTTTTGCATATCCGTGGTA-3′
A33R 5′-GATCGAATTCTAAAATGATGACACCAGAAAACG-3′ 584 pTA33R
5′-AAGCTTCTCGAGTTAGTTCATTGTTTTAACACAAA-3′
A34R 5′-GATCGAATTCTAAAATGAAATCGCTTAATAGAC-3′ 533 pTA34R
5′-AAGCTTCTCGAGTCACTTGTAGAATTTTTTAACAC-3′
A56R 5′-CCCGGGATCCTAAAATGACACGATTACCAATACTTTTG-3′ 975 pTA56R
5′-CGGGCTCGAGTTAGACTTTGTTCTCTGTTTTG-3′
B5R 5′-CCGAGTCGACAAAATGAAAACGATTCCCGTTG-3′ 980 pTB5R
5′-CCCGGGCTCGAGTTACGGTAGCAATTTATGGAAC-3′
A36R 5′-GATCGAATTCTAAAATGATGCTGGTACCTCTTATC-3′ 692 pTA36R
5′-AAGCTTCTCGAGTTACACCAATGATACGACC-3′
L1R 5′-TATTTAAATGGGTGCCGCAGC-3′ 779 pTL1R
5′-TTTTCAGTTTTGCATATCCGTGGTA-3′
PCR products were cloned into pTarget and were DNA sequenced. Initiation and stop codons are shown underlined for the forward and reverse primers,
respectively.
(Antigen Pharmaceuticals Ltd. Co., Tipperary, Ire) in PBS.
Vaccine was applied in a total volume of 100l per mouse
as two 25l intramuscular doses at two points on each hind
limb. Vaccines were administered at 3-week intervals and
blood samples were taken 1-week post-immunisation.
2.3. Virus production
Vaccinia virus IHD (ATCC VR156) was grown in RK13
cells in Dulbecco’s MEM supplemented with 2% foetal
bovine serum (FBS) 3 mM glutamine and 100 units/ml
penicillin and streptomycin. IMV and EEV was prepared
by infecting RK13 cell monolayers with VACV IHD at
a multiplicity of infection (MOI) of 10 for 1 h, wash-
ing the cell sheet with PBS and adding fresh medium.
After 24 h, EEV contained in culture medium was col-
lected, centrifuged at 3000 × g for 5 min to pellet de-
bris and then again at 80,000 × g for 60 min to pellet
EEV. IMV was harvested from the infected RK13 cells
at 48 h post-infection by layering the contents of Dounce
homogenised infected cells onto a 36% (w/v) sucrose
cushion and ultra-centrifuging at 80,000 × g for 80 min.
Virus pellets were resuspended in PBS, titred and stored at
−80 ◦C.
Purified virus or cell homogenates were heat inactivated
at 60 ◦C for 2 h in 100l aliqouts on a PCR thermal block.
Ten percent of inactivated virus was put into culture for 7
days to monitor for viral sterility.
2.4. Mouse challenges
After four vaccine doses, given at intervals of 3 weeks,
mice were intranasally challenged with 100 MLD50 (equiv-
alent to 1.0 × 107 pfu per mouse) of VACV IHD admin-
istered as 10l to a single nares. Challenge took place 3
weeks after the final immunisation. Daily weights and clin-
ical signs of disease were taken for groups of five or six
mice. Humane endpoints for this model have been previ-
ously established as either 30% body weight loss, or acute
clinical signs such as blindness or severe breathing difficul-
ties. Individual mice were assessed daily for signs of disease
and these were assigned numerical scores from 0 (normal),
1 (slightly ruffled), 2 (ruffled), 3 (hunched), 4 (oedema, res-
piratory distress) to 5 (death or humane endpoint). The sum
for each group was expressed as a percentage plotted against
time (see Fig. 2), where 100% represents no survivors in a
group. Groups with scores below 33.3% exhibited mild clin-
ical signs (protection equivalent to mice scarified with live
smallpox vaccine), those between 33.3 and 66.7% exhibited
significant clinical signs (some protection) and groups with
scores above 66.7% had severe and fatal clinical signs of
disease (little or no protection).
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2.5. Measuring anti-VACV antibodies
VACV infected cell extract (VICE) antigen was gener-
ated from Dounce homogenised VACV IHD infected RK13
cells in PBS. Cell homogenates were centrifuged at 300×g
for 10 min to pellet cell nuclei, supernates were dispensed
into 1ml aliquots and stored at −20 ◦C. Ninety-six-well mi-
crotitre plates (Immulon-2 HB, Thermolabsystems) were
coated overnight at 4 ◦C with mock-infected or IHD infected
RK13 cell extracts in carbonate–bicarbonate buffer (Sigma).
Excess binding capacity was adsorbed with Blotto (5% dried
milk powder in PBS) for 2 h at 37 ◦C, and mouse primary
antibodies and goat anti-mouse Ig G HRP at 1/1000 (Bio-
rad) were applied for 1 h at 37 ◦C. Plates were washed three
times with PBS supplemented with 0.05% Tween-20. Anti-
gen was coated onto ELISA plates at twice the antigen con-
centration that produced a maximum optical density (OD)
with VACV Lister antisera. Experimental mouse sera were
diluted at 1/50 in duplicate wells and were considered pos-
itive if they had an OD that was twice the OD obtained for
a normal mouse serum. ABTS reagent (Sigma) was used to
quantitate antibody binding.
2.6. Measuring IFNγ and IL-5
Female BALB/c mice were immunised as described. Two
weeks after immunisation mice were culled and spleens re-
moved and dispersed to single cells. Spleen cells (3 × 105)
were cultured in 96-well round-bottomed microtitre plates
in 200l volumes of RPMI 1640 medium supplemented
with 10% FBS, 3 mM glutamine, 20M 2-mercaptoethanol
and 50g/ml gentamycin, in the presence of 5g/ml
concanavalin-A (ConA) or 100g/ml heat-inactivated VICE
or extracellular envelope virus (EEV). After 72 h of culture,
supernates were removed and stored at −80 ◦C. Secreted
cytokines were measured by ELISA using pre-standardised
Pharmingen OPT EIA kits. IFN was measured as an
Table 3
Summary illustrating the performance of the 10 DNA vaccines in BALB/c female mice challenged with a lethal intranasal challenge dose of VACV IHD
Particle type DNA vaccine gene insert Survivors after challenge (%) Mean lowest body weight (%) VACV antibody
IMV A13L 0 (0/5) <70 0/5
A27L 80 (4/5) 85.0 0/5
D8L 50 (3/6) 73.4 4/6
H3L 33 (2/6) 73.1 0/6
L1R 0 (0/6) <70 0/6
EEV A33R 67 (4/6) 79.7 4/6
A34R 0 (0/5) <70 0/5
A56R 50 (3/6) 77.0 5/6
B5R 100 (5/5) 93.7 4/5
IEV A36R 60 (3/5) 80.3 0/5
Controls Lister 100 (4/4) 97.7 4/4
pTarget 0 (0/11) <70 0/11
PBS 0 (0/11) <70 0/11
The presence of VACV antibody was measured by ELISA using VICE antigen. Body weight losses below 30% were not exceeded.
indication of a T cell type 1 (Tc1) cytokine bias and IL-5
as an indication of a Tc2 cytokine bias.
3. Results
3.1. Identifying protective membrane protein antigens
We developed a BALB/c mouse challenge model to eval-
uate the performance of different VACV envelope proteins
expressed via a DNA vaccine vector. Ten membrane protein
genes (Table 3) were cloned into the mammalian plasmid
expression vector pTarget. Five IMV, one IEV and four EEV
genes were screened for their ability to protect groups of fe-
male BALB/c mice from an intranasal lethal challenge with
VACV IHD.
Animals receiving DNA vaccines with the D8L, A33R,
A56R and B5R genes were frequently sero-positive against
VACV antigen as analysed by ELISA (Table 2). However,
the production of anti-VACV reactivity was generally mod-
est, inconsistent for recipients of a given vaccine, and re-
quired a minimum of two DNA immunisations (data not
shown).
Mice were given an intranasal challenge with 100 MLD50
of VACV IHD 3 weeks after four vaccine doses, given
at intervals of 3 weeks. Eighty percent of mice receiving
pTA27L, 50% receiving pTD8L and 33% receiving the
pH3L DNA vaccines were protected from this challenge
(Table 2 and Fig. 1a). No mice survived this challenge after
receiving the pTL1R or the pTA13L DNA vaccines. Time to
death was shorter for the pTA13L group than for the pTar-
get control group. Hundred percent survival was achieved
following challenge by scarification with live Lister strain.
The A27L DNA vaccine was the only IMV membrane
antigen offering a good level of protection.
The EEV and IEV antigens also included some promis-
ing candidates. All mice receiving the pTB5R DNA vaccine
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Fig. 1. Survival of groups of BALB/c mice immunised with four doses
of DNA vaccine for IMV (a) or EEV/IEV (b) antigens and intranasally
challenged with 100 MLD50 of VACV IHD. Animals were weighed daily
from day 0 (not shown) and were culled if body weight dropped below
30% or if their clinical signs were very severe.
and 66% of mice vaccinated with pTA33R were protected.
Sixty percent of pTA36R and 50% of pTA56R DNA vac-
cinated mice had a body weight loss of <30%, but these
two groups exhibited severe signs of disease post-challenge
and occasionally relapsed during the recovery phase (data
not shown). This indicated that the pTA36R and pTA56R
vaccines produced incomplete protection. None of the mice
receiving either pTA34R DNA vaccine, PBS or the pTar-
get empty expression vector survived the challenge. The
pTB5R DNA vaccine was the only subunit vaccine that pro-
vided 100% protection against a large 100 MLD50 VACV
intranasal challenge.
3.2. The efficacy of the B5R, A27L and A33R
DNA vaccines
Percentage weight loss was considered to be the best ob-
jective clinical measurement of vaccine performance against
challenge. Final mean percentage weight loss for each group
was calculated by taking the minimum weight for each
animal over the 14-day challenge, and expressing this as
a percentage of the animal’s weight immediately prior to
challenge. These values were then averaged for the group
(Table 3). The pTB5R vaccine produced the best DNA vac-
cine score with a final mean weight loss of just 7.3%, fol-
lowed by pTA27L 15% and pTA33R with 20.3% (Table 3).
To evaluate how weight loss and signs of disease correlated
a scoring scheme was devised that reflected severity. Indi-
vidual animals were scored daily from zero to five and these
scores were summed and plotted as histograms alongside the
daily mean percentage weight loss for the group. Data from
the empty vector and our three best performing vaccines are
shown in Fig. 2. By day 10 the pTarget control group had no
survivors and had a maximum disease score and no further
daily mean body weight measurement (Fig. 2a). Both the
pTA33R (Fig. 2b) and pTA27L (Fig. 2c) DNA vaccines had
steep drops in daily body weight up to day 7 and then began
to recover. The pTB5R DNA vaccine (Fig. 2d) had the low-
est disease score and a shallow weight loss profile relative
to the control or the two other vaccines. The rate of recovery
as measured by disease signs for the pTB5R DNA vaccine
after 7 days post-challenge was much improved compared
with pTA33R and pTA27L. This was not apparent from the
mean weight loss curve as the pTA33R and pTA27L DNA
vaccines did not confer 100% protection (Table 3), and so
the data represents survivors only. Final mean percentage
weight loss (Table 3) and daily disease scores (Fig. 2) in-
cluded all mice whether or not they survived. The order of
efficacy for the three best DNA vaccine candidates as mea-
sured by survival, disease score and weight loss was B5R >
A27L > A33R.
3.3. The effect of pTB5R dosing on protection
The effect of multiple pTB5R DNA vaccine dosing was
measured to establish the relative magnitude of protection
after two, three or four doses of vaccine. All recipients of
these pTB5R dose regimes survived the challenge. Fig. 3
shows the effect of dose on protection for a period from
0 to 8 days post-challenge as measured by daily mean
percentage weight loss. Up to day 4 post-challenge, a
two dose regime was similar to the four dose regime as
judged by change in body weight. However, from day 5
onwards the protection was less apparent for the two dose
group. Over a 14-day period post-challenge mice receiv-
ing three doses of pTB5R DNA vaccine had the smallest
percentage mean minimum weight loss 8.0%, compared
with 11.0% for the four dose and 17.2% for the two dose
regimes.
3.4. Antigen-specific T cell recall responses in pTB5R
vaccinated mice
We had observed that antibody was produced by most
but not all recipients of the pTB5R DNA vaccine (Table 3).
The absence of antibody in mice that were otherwise
protected suggests that pTB5R was also capable of induc-
ing a cell-mediated immune response which could be the
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Fig. 2. Combination charts displaying the course of disease in DNA vaccinated groups of BALB/c mice after challenge with 100 MLD50 of VACV IHD.
The charts display the relationship between percent disease score (shown as columns) and percent mean body weight loss (line) with time post-challenge.
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Fig. 3. Effect of vaccine dose on protection from a lethal intranasal VACV challenge. Percentage change in daily mean body weight between days 0
and 8 in mice immunised with two, three or four doses of pTB5R DNA vaccine. Values are shown adjacent to the final data points for all DNA dose
regimes on day 8.
basis of protection. To study this we measured IFN and
IL-5 responses of EEV-stimulated T cells from vaccinated
mice as an indication of a type 1 (inflammatory) or type
2 (anti-inflammatory) cytokine bias. BALB/c mice were
immunised once, twice, three or four times with 50g
doses of pTB5R and then spleen cells were harvested and
stimulated in vitro for 3 days with or without inactivated
purified EEV, a rich source of the B5R protein. IFN and
IL-5 in the culture supernatants were measured using a
quantitative ELISA. No IL-5 production was observed in any
pTB5R vaccine group (data not shown). However, strong
EEV-induced IFN responses were measured in groups of
mice given one dose of vaccine with moderate and variable
responses for groups given two, three and four doses (Fig. 4).
Whilst the mean value in the other dose regimes was lower
than for one vaccine dose, individual animals did produce
up to 2000 pg/ml of IFN in all dose regimes. The priming
dose gave the greatest and most consistent cytokine recall.
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Fig. 4. Effect of dosing with pTB5R to generate a Tc1-mediated memory
immune response as measured by the production of IFN in antigen
stimulated spleen cells. Groups of four BALB/c mice were immunised
once, twice, three or four times at 3-week intervals with 50g of plasmid
DNA in 0.25% bupivicaine. Two weeks after each immunisation spleen
cells were harvested and grown in vitro in the presence of 100g/ml
of heat-inactivated mock (0) or VACV IHD EEV. After 72 h culture,
supernatants were stored at −20 ◦C, and then samples were collectively
assayed by ELISA using the Pharmingen OPT EIA kits. Standard curves
were plotted using recombinant cytokine to enable accurate cytokine
quantification.
We vaccinated C57BL6 mice with pTB5R to further de-
termine the cellular origin of the IFN (Fig. 5). Unimmu-
nised C57BL6 mice did not produce any IFN recall with
VICE, except that one out of seven mice did respond to
EEV. pTB5R immunised C57BL6 mice produced variable
IFN responses, in a pattern resembling that for BALB/c
3 x pTB5R immunised B6 and B6-MHC
class I knock out mice
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Fig. 5. Monitoring the IFN in vitro recall response to VICE or EEV
antigens in C57BL/6 or MHC-I knockout mice immunised with pTB5R.
Mice were either unimmunised (seven) or immunised (four) with three
50g doses of pTB5R at 3-week intervals. Two weeks after the final
immunisation spleen cells were harvested and grown in vitro in the pres-
ence of 100g/ml of heat-inactivated mock (0), heat-inactivated VICE,
heat-inactivated EEV antigen or 5g/ml ConA. After 72 h culture super-
natants were treated as described in Fig. 4.
immunised mice (Fig. 4). One of the four DNA immu-
nised C57BL6 mice also produced a strong IFN response
(2000 pg/ml) against VICE antigen (Fig. 5). Interestingly,
all four pTB5R immunised C57BL6 MHCI knockout trans-
genic mice produced strong antigen-specific recall responses
(>3000 pg/ml) in response to EEV antigen that was equiv-
alent to the response obtained with the polyclonal mitogen
ConA. Reduced memory responses were also measured in
VICE antigen stimulated C57BL6 MHCI spleen cells that
perhaps reflects the lower concentration of the B5R antigen
in this preparation.
4. Discussion
A DNA vaccine based on the VACV B5R gene is shown
here to provide 100% survival at 14 days post-challenge in
a mouse model that attempts to mimic aspects of the natu-
ral route of smallpox infection in man. Other envelope pro-
tein genes had different abilities to protect mice against a
lethal intranasal challenge with VACV, as vaccines based
on the A27L, A33R, A36R, A56R and D8L genes all pro-
vided greater than 50% survival at 14 days post-challenge
(Fig. 1). Three envelope protein genes, A34R, A13L and
L1R did not provide any protection against challenge in this
study. To date this is the most extensive published survey of
individual VACV genes in a single lethal challenge model.
The challenge model represents the route of natural infec-
tion with smallpox more closely than for other routes (i.e.
intra-peritoneal or cardiac infusion), because the challenge
virus infects the host via the mucosal surfaces of the respi-
ratory tract before it travels to other tissues and organs. The
model therefore maximises the relevance to smallpox air-
borne infection of the immune mechanisms of action elicited
by the individual vaccine candidates.
Our studies and those of Galmiche et al. [16] used a res-
piratory challenge model and have produced similar find-
ings, though our study used a 10-fold higher challenge dose
of VACV IHD. The survival rates in the study of Galmiche
et al. [16] were 100% for A33R, 82% for B5R, 50% for
A36R and 18% for A34R. Interestingly, these authors found
that the A33R gene, not the B5R gene, provided the most
complete protection, but their results also showed that B5R
vaccinated mice recovered faster than the A33R mice by
weight measurement, suggesting that the B5R vaccine was
effective. Our results broadly support the findings of [16],
and indicate that A33R and B5R are both effective DNA
vaccine candidates. We show that the B5R DNA vaccine in-
vokes a potent IFN production in vitro upon exposure to
EEV antigen that might be the basis of conveyed protection
in vivo.
Another study that used different challenge and immu-
nisation routes produced different results with the same
DNA vaccine candidates used in our study. Hooper et al.
[17,18] looked at the individual and the combined effects of
A27L, A33R, L1R and B5R by gene-gun immunisation in a
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challenge model that used 5×108 pfu VACV (WR strain) cell
lysate (12 LD50) administered by the intraperitoneal route.
After three gene-gun immunisations with 0.5–1g of DNA,
only 10% of A27L, 40% of B5R [18] and 70% of A33R [17]
DNA vaccine recipients survived the challenge. The A27L
gene product (p14k fusion protein) stimulates neutralising
antibody in the context of an infection with live VACV. These
authors demonstrated that the A27L DNA vaccine produced
neutralising antibody titres of 1/160 to >1/640, but the use of
a challenge preparation containing free antigen could com-
pete with challenge virus for antibody binding. This may
conceivably have lead to an underestimation of the protec-
tive efficacy of the A27L-based vaccine, and indeed for other
candidates in their study which induced significant levels of
antibody. However, the L1R gene produced 80% protection
in the study by Hooper et al. [17], but the L1R gene pro-
vided no protection in the study we report here. There is
no obvious explanation for this discrepancy, which suggests
that some of the differences between the two studies may
be the result of potential artefacts such as expression levels
from DNA constructs, route of immunisation, the strain of
challenge virus and/or route of challenge.
pTB5R, pTA33R, pTA56R and pTD8L were the only
DNA vaccines that produced anti-VACV circulating anti-
body in this study, but sero-conversion was inconsistent and
the titres achieved by ELISA with VICE antigen were mod-
est (<1/100) (Table 3). In subsequent experiments, we have
found that pTA27L can induce antibody in a small propor-
tion of vaccinees (data not shown). However, the ability of
pTA27L to provide 80% protection (Fig. 1) in the absence
of any measurable antibody (Table 3) implies that other im-
mune mechanisms are activated by the pTA27L vaccine.
This is also true for some animals receiving the pTB5R and
pTA33R vaccines.
Consistent sero-conversion was obtained with all four
DNA vaccines studied by [17,18] and strong neutralising
antibody titres were achieved for A27L and L1R, which
implies that gene-gun administration improves the humoral
immune response. The gene gun injects DNA efficiently
into subcutaneous tissues, where dendritic cells may be ex-
pected to encounter the DNA and any antigen that is pro-
duced from it. In our own study, and that of [16] immunisa-
tion was by intramuscular injection. This places the antigen
source in an immunologically different environment to that
used by Hooper et al. [17,18] and this may be a significant
factor in the differential induction of antibody, and survival
post-challenge in the three studies.
As antibody was not a correlate of protection in our study,
we then went on to determine if the pTB5R vaccine was
stimulating a Tc1-type response. We measured strong IFN
production in in vitro stimulated spleen cells from vacci-
nated animals, which is indicative of a type 1 T cell (inflam-
matory) cytokine bias in the response. IFN was produced
at high levels immediately after a single vaccination. Addi-
tional immunisations did not appear to enhance IFN pro-
duction but a gradual increase in IFN upon boosting was
observed and might represent the tail of rapid but decaying
large secondary responses. Further studies are necessary to
illuminate the dynamics of IFN production in BALB/c mice
and reveal how primary and secondary immune responses
impact on this important cytokine’s synthesis.
The functions of IFN include stimulating expression of
MHC class I and II and activation of macrophages and NK
cells, and it plays a major role in enhancing the adaptive
immune response. We then used a different mouse genetic
background with the C57BL6 strain to determine whether
CD4 or CD8 T cells were the predominant source of IFN
(Fig. 5). C57BL6 mice produced variable antigen-specific
memory responses after three vaccine doses similar to vac-
cinated BALB/c mice (Fig. 4). However, the C57BL6 MHC
class I knockout mice, which lack most CD8+ cells, con-
sistently produced high levels of IFN in response to in
vitro recall with EEV antigen, suggesting that CD4+ T cells
were the main source of IFN in these mice. Although
equal numbers of spleen cells were used from each mouse
strain, the absence of CD8+ cells in C57BL6 MHC class I
knockout spleens must bias the cell composition in favour
of CD4+ cells. In addition, our use of inactivated virus anti-
gen to measure memory responses excluded the opportunity
to measure significant CD8 responses. Only quantitative flu-
orescent staining of CD4 and CD8 cells for IFN in these
mice will reveal the full nature of the IFN dynamic with
these mice strains.
Poxviruses have evolved strategies to modulate the effects
of IFN production. VACV produces a soluble IFN recep-
tor molecule (B8R gene) that serves to bind and sequester
soluble IFN, and other poxviruses have been shown to en-
code proteins that interact with IFN or its receptors [19,20].
The fact that poxviruses specifically modulate this cytokine
suggests that IFN might have an important role in develop-
ing a protective immune response. Recent studies with the
live smallpox vaccine indicate that IFN producing human
T cell responses are a consistent marker after vaccination
[21]. Our data suggest that IFN production post-vaccination
may prove to be an important correlate of immunity for any
eventual subunit or DNA vaccine against OPV infection.
Further work is required to understand the mechanisms
of protection that are induced by the pTB5R and other DNA
vaccines, and to establish definitive correlates of immunity.
Our work and that of others indicate that antibody is not
the only source of protection. The DNA vaccines examined
here do confer some level of cell-mediated immunity, and
understanding this immune response will be important if a
safe subunit or DNA alternative to live smallpox vaccine is
to be developed.
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